By up-regulating the expression of IRF5 and down-regulating CCL5, it promotes the transformation of M2 tumor-associated macrophages, reprograms the tumor microenvironment immunology, and achieves substantial reduction in postsurgical pancreatic tumor regrowth. The gene discussed is IRF5; the disease is neoplasm.